Peter Nielsen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

. We fall into the mess. Unelected bureaucrats shouldnt write laws. Who are they working for . All the bureaucracy of Government Works for the president. We have abdicated our role as congress. The regulations are 20,000 pages. So much of it is being done without our knowledge. There is a debate over defunding the immigration executive order. I am for that and about 1000 other things on every bill. People say you were trying to tie the hands of the president. Thats our job. I dont care if its a republican president. The power of the purse, that is instructions. As a consequence, they do many t...

Apple. The arm down 2. 5 . You can see this playing out in the markets. Lets move to another company that reported. That is siemens. Hans, youre watching details there. They have a strong future but revenues down 3 from the year before. The first full quarter of a report card for the new c. E. O. Well see how the it reacts through the day on the trading floor. Jon, lets come to you on the Broader Market picture. Emerging markets, things looking a little calmer perhaps . The calm after the storm. U. K. G. D. P. Which manus is on and the Federal Reserve meets today. Very interesting. Youre looki...

Lawyers for Michael Flynn informed mr. Trumps legal team they are no longer able to discuss the special counsels investigation. That could mean flynn is cooperating with prosecutors. Were getting very close here to a potential showdown between the Trump Administration and the special counsel. Embattled Senate Candidate roy moore is now going on the offensive. I dont know them. Ive never known them. This was a complete shock. Its unclear exactly weather his campaign is planning to pursue legal action. Ive been here a little bit more than 24 hours now. Black friday could be the last for american...

Shares of Bio-Path Holdings, Inc. (BPTH) soared 90% on Thursday after it announced the successful completion of the higher dose second cohort in phase 1/1b clinical trial of BP1002 in refractory/relapsed Acute Myeloid Leukemia (AML) patients.

Bio-Path Holdings shares are trading higher Thursday after the company announced the completion of its second dose cohort in Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia patients.